Cargando…

Efficacy of a 14-day quadruple-therapy regimen for third-line Helicobacter pylori eradication

PURPOSE: To assess the efficacy of amoxicillin, tetracycline, high-dose metronidazole, and a proton-pump inhibitor for third-line Helicobacter pylori eradication. METHODS: We enrolled 70 consecutive patients who had registered, failed to respond to two rounds of H. pylori eradication, and undergone...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Hsiang Tso, Wang, Hsin-Ming, Yang, Shih-Cheng, Tai, Wei-Chen, Liang, Chih-Ming, Wu, Keng-Liang, Lee, Chen-Hsiang, Chuah, Seng-Kee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214414/
https://www.ncbi.nlm.nih.gov/pubmed/30464550
http://dx.doi.org/10.2147/IDR.S185511
_version_ 1783367975789658112
author Huang, Hsiang Tso
Wang, Hsin-Ming
Yang, Shih-Cheng
Tai, Wei-Chen
Liang, Chih-Ming
Wu, Keng-Liang
Lee, Chen-Hsiang
Chuah, Seng-Kee
author_facet Huang, Hsiang Tso
Wang, Hsin-Ming
Yang, Shih-Cheng
Tai, Wei-Chen
Liang, Chih-Ming
Wu, Keng-Liang
Lee, Chen-Hsiang
Chuah, Seng-Kee
author_sort Huang, Hsiang Tso
collection PubMed
description PURPOSE: To assess the efficacy of amoxicillin, tetracycline, high-dose metronidazole, and a proton-pump inhibitor for third-line Helicobacter pylori eradication. METHODS: We enrolled 70 consecutive patients who had registered, failed to respond to two rounds of H. pylori eradication, and undergone endoscopy for H. pylori culture. Seven patients were lost to follow-up. Patients were treated according to the results of antibiotic-susceptibility testing reports (cultured group, n=39). Those who failed the H. pylori culture were prescribed 14-day quadruple therapy containing esomeprazole 40 mg twice daily, amoxicillin 1 g twice daily, tetracycline 500 mg four times daily, and metronidazole 500 mg three times daily (empirical group, n=24). A follow-up urea breath test was performed 8 weeks later. RESULTS: Antibiotic-resistance rates were 79.5% (clarithromycin), 94.9% (levofloxacin), 66.7% (metronidazole), 2.6% (amoxicillin), and 0 (tetracycline). Eradication rates attained by the cultured and empirical group were 89.7% (95% CI 72.7%–97.1%) and 58.3% (95% CI 36.6%–77.9%) in per-protocol analysis (P=0.004) and 81.4% (95% CI 66.6%–91.6%) and 51.8% (95% CI 31.9%–71.3%) in intention-to-treat analysis (P=0.014), respectively. Culture-guided therapy was the only clinical factor influencing the efficacy of H. pylori eradication (OR 0.16, 95% CI 0.04–0.60; P=0.006). Despite the high metronidazole-resistance rate (66.7%) after two treatment failures, the eradication rate in patients with this condition was 84%. CONCLUSION: Empirical 14-day modified quadruple therapy is not acceptable as an alternative third-line rescue H. pylori treatment. The success rate of third-line susceptibility-guided treatment was near 90%. This report is valuable as a reminder to medical practitioners that rather than a try-and-see approach, susceptibility-guided therapy should always be considered whenever possible for patients who have undergone several treatment failures.
format Online
Article
Text
id pubmed-6214414
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-62144142018-11-21 Efficacy of a 14-day quadruple-therapy regimen for third-line Helicobacter pylori eradication Huang, Hsiang Tso Wang, Hsin-Ming Yang, Shih-Cheng Tai, Wei-Chen Liang, Chih-Ming Wu, Keng-Liang Lee, Chen-Hsiang Chuah, Seng-Kee Infect Drug Resist Original Research PURPOSE: To assess the efficacy of amoxicillin, tetracycline, high-dose metronidazole, and a proton-pump inhibitor for third-line Helicobacter pylori eradication. METHODS: We enrolled 70 consecutive patients who had registered, failed to respond to two rounds of H. pylori eradication, and undergone endoscopy for H. pylori culture. Seven patients were lost to follow-up. Patients were treated according to the results of antibiotic-susceptibility testing reports (cultured group, n=39). Those who failed the H. pylori culture were prescribed 14-day quadruple therapy containing esomeprazole 40 mg twice daily, amoxicillin 1 g twice daily, tetracycline 500 mg four times daily, and metronidazole 500 mg three times daily (empirical group, n=24). A follow-up urea breath test was performed 8 weeks later. RESULTS: Antibiotic-resistance rates were 79.5% (clarithromycin), 94.9% (levofloxacin), 66.7% (metronidazole), 2.6% (amoxicillin), and 0 (tetracycline). Eradication rates attained by the cultured and empirical group were 89.7% (95% CI 72.7%–97.1%) and 58.3% (95% CI 36.6%–77.9%) in per-protocol analysis (P=0.004) and 81.4% (95% CI 66.6%–91.6%) and 51.8% (95% CI 31.9%–71.3%) in intention-to-treat analysis (P=0.014), respectively. Culture-guided therapy was the only clinical factor influencing the efficacy of H. pylori eradication (OR 0.16, 95% CI 0.04–0.60; P=0.006). Despite the high metronidazole-resistance rate (66.7%) after two treatment failures, the eradication rate in patients with this condition was 84%. CONCLUSION: Empirical 14-day modified quadruple therapy is not acceptable as an alternative third-line rescue H. pylori treatment. The success rate of third-line susceptibility-guided treatment was near 90%. This report is valuable as a reminder to medical practitioners that rather than a try-and-see approach, susceptibility-guided therapy should always be considered whenever possible for patients who have undergone several treatment failures. Dove Medical Press 2018-10-30 /pmc/articles/PMC6214414/ /pubmed/30464550 http://dx.doi.org/10.2147/IDR.S185511 Text en © 2018 Huang et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Huang, Hsiang Tso
Wang, Hsin-Ming
Yang, Shih-Cheng
Tai, Wei-Chen
Liang, Chih-Ming
Wu, Keng-Liang
Lee, Chen-Hsiang
Chuah, Seng-Kee
Efficacy of a 14-day quadruple-therapy regimen for third-line Helicobacter pylori eradication
title Efficacy of a 14-day quadruple-therapy regimen for third-line Helicobacter pylori eradication
title_full Efficacy of a 14-day quadruple-therapy regimen for third-line Helicobacter pylori eradication
title_fullStr Efficacy of a 14-day quadruple-therapy regimen for third-line Helicobacter pylori eradication
title_full_unstemmed Efficacy of a 14-day quadruple-therapy regimen for third-line Helicobacter pylori eradication
title_short Efficacy of a 14-day quadruple-therapy regimen for third-line Helicobacter pylori eradication
title_sort efficacy of a 14-day quadruple-therapy regimen for third-line helicobacter pylori eradication
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214414/
https://www.ncbi.nlm.nih.gov/pubmed/30464550
http://dx.doi.org/10.2147/IDR.S185511
work_keys_str_mv AT huanghsiangtso efficacyofa14dayquadrupletherapyregimenforthirdlinehelicobacterpylorieradication
AT wanghsinming efficacyofa14dayquadrupletherapyregimenforthirdlinehelicobacterpylorieradication
AT yangshihcheng efficacyofa14dayquadrupletherapyregimenforthirdlinehelicobacterpylorieradication
AT taiweichen efficacyofa14dayquadrupletherapyregimenforthirdlinehelicobacterpylorieradication
AT liangchihming efficacyofa14dayquadrupletherapyregimenforthirdlinehelicobacterpylorieradication
AT wukengliang efficacyofa14dayquadrupletherapyregimenforthirdlinehelicobacterpylorieradication
AT leechenhsiang efficacyofa14dayquadrupletherapyregimenforthirdlinehelicobacterpylorieradication
AT chuahsengkee efficacyofa14dayquadrupletherapyregimenforthirdlinehelicobacterpylorieradication